{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T15:44:45Z","timestamp":1774021485165,"version":"3.50.1"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,3,20]]},"DOI":"10.7759\/cureus.105557","type":"journal-article","created":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T14:47:12Z","timestamp":1774018032000},"source":"Crossref","is-referenced-by-count":0,"title":["Rapid Reduction in Proteinuria With the Initiation of Voclosporin in Lupus Nephritis: A Single-Center Experience"],"prefix":"10.7759","author":[{"given":"Homa","family":"Timlin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johnson","family":"Ong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Duvuru","family":"Geetha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohamed G","family":"Atta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ihab","family":"Kamel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Boyoung","family":"Ahn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Timothy","family":"Kaniecki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.7326\/AITC202006020","article-title":"Systemic lupus erythematosus","volume":"172","author":"Kiriakidou M","year":"2020","unstructured":"Kiriakidou M, Ching CL. Systemic lupus erythematosus. Ann Intern Med. 2020, 172:ITC81-96. 10.7326\/AITC202006020","journal-title":"Ann Intern Med"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2022.102871","article-title":"Lupus nephritis: new progress in diagnosis and treatment","volume":"132","author":"Yu C","year":"2022","unstructured":"Yu C, Li P, Dang X, Zhang X, Mao Y, Chen X. Lupus nephritis: new progress in diagnosis and treatment. J Autoimmun. 2022, 132:102871. 10.1016\/j.jaut.2022.102871","journal-title":"J Autoimmun"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2016.03.042","article-title":"Insights into the epidemiology and management\u00a0of\u00a0lupus nephritis from the\u00a0US\u00a0rheumatologist's perspective","volume":"90","author":"Hoover PJ","year":"2016","unstructured":"Hoover PJ, Costenbader KH. Insights into the epidemiology and management\u00a0of\u00a0lupus nephritis from the\u00a0US\u00a0rheumatologist's perspective. Kidney Int. 2016, 90:487-92. 10.1016\/j.kint.2016.03.042","journal-title":"Kidney Int"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kev311","article-title":"The frequency and outcome of lupus nephritis: results from an international inception cohort study","volume":"55","author":"Hanly JG","year":"2016","unstructured":"Hanly JG, O'Keeffe AG, Su L, et al.. The frequency and outcome of lupus nephritis: results from an international inception cohort study. Rheumatology (Oxford). 2016, 55:252-62. 10.1093\/rheumatology\/kev311","journal-title":"Rheumatology (Oxford)"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2019.10.017","article-title":"Update on lupus nephritis: core curriculum 2020","volume":"76","author":"Parikh SV","year":"2020","unstructured":"Parikh SV, Almaani S, Brodsky S, Rovin BH.  Update on lupus nephritis: core curriculum 2020. Am J Kidney Dis. 2020, 76:265-81. 10.1053\/j.ajkd.2019.10.017","journal-title":"Am J Kidney Dis"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1002\/art.38220","article-title":"End-stage renal disease in African Americans with lupus nephritis is associated with APOL1","volume":"66","author":"Freedman BI","year":"2014","unstructured":"Freedman BI, Langefeld CD, Andringa KK, et al.. End-stage renal disease in African Americans with lupus nephritis is associated with APOL1. Arthritis Rheumatol. 2014, 66:390-6. 10.1002\/art.38220","journal-title":"Arthritis Rheumatol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/s0272-6386(00)70262-9","article-title":"Factors predictive of outcome in severe lupus nephritis","volume":"35","author":"Korbet SM","year":"2000","unstructured":"Korbet SM, Lewis EJ, Schwartz MM, et al.. Factors predictive of outcome in severe lupus nephritis. Am J Kidney Dis. 2000, 35:904-14. 10.1016\/s0272-6386(00)70262-9","journal-title":"Am J Kidney Dis"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1002\/acr.20397","article-title":"Identification of biomarkers that predict response to treatment of lupus nephritis with mycophenolate mofetil or pulse cyclophosphamide","volume":"63","author":"Dall'Era M","year":"2011","unstructured":"Dall'Era M, Stone D, Levesque V, Cisternas M, Wofsy D. Identification of biomarkers that predict response to treatment of lupus nephritis with mycophenolate mofetil or pulse cyclophosphamide. Arthritis Care Res (Hoboken). 2011, 63:351-7. 10.1002\/acr.20397","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kel360","article-title":"Urine protein-to-creatinine ratio in an untimed urine collection is a reliable measure of proteinuria in lupus nephritis","volume":"46","author":"Leung YY","year":"2007","unstructured":"Leung YY, Szeto CC, Tam LS, et al.. Urine protein-to-creatinine ratio in an untimed urine collection is a reliable measure of proteinuria in lupus nephritis. Rheumatology (Oxford). 2007, 46:649-52. 10.1093\/rheumatology\/kel360","journal-title":"Rheumatology (Oxford)"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1002\/acr.21664","article-title":"American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis","volume":"64","author":"Hahn BH","year":"2012","unstructured":"Hahn BH, McMahon MA, Wilkinson A, et al.. American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis. Arthritis Care Res (Hoboken). 2012, 64:797-808. 10.1002\/acr.21664","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1002\/art.43212","article-title":"2024 American College of Rheumatology (ACR) guideline for the screening, treatment, and management of lupus nephritis","volume":"77","author":"Sammaritano LR","year":"2025","unstructured":"Sammaritano LR, Askanase A, Bermas BL, et al.. 2024 American College of Rheumatology (ACR) guideline for the screening, treatment, and management of lupus nephritis. Arthritis Rheumatol. 2025, 77:1115-35. 10.1002\/art.43212","journal-title":"Arthritis Rheumatol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1002\/art.39594","article-title":"Risk of end-stage renal disease in patients with lupus nephritis, 1971-2015: a systematic review and Bayesian meta-analysis","volume":"68","author":"Tektonidou MG","year":"2016","unstructured":"Tektonidou MG, Dasgupta A, Ward MM. Risk of end-stage renal disease in patients with lupus nephritis, 1971-2015: a systematic review and Bayesian meta-analysis. Arthritis Rheumatol. 2016, 68:1432-41. 10.1002\/art.39594","journal-title":"Arthritis Rheumatol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1136\/lupus-2022-000773","article-title":"Response to therapy at 6 months predicts long-term renal outcome in lupus nephritis with poor kidney function","volume":"9","author":"Luo H","year":"2022","unstructured":"Luo H, Zhou Y, Chen G, et al.. Response to therapy at 6 months predicts long-term renal outcome in lupus nephritis with poor kidney function. Lupus Sci Med. 2022, 9:e000773. 10.1136\/lupus-2022-000773","journal-title":"Lupus Sci Med"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1002\/art.20666","article-title":"Early response to immunosuppressive therapy predicts good renal outcome in lupus nephritis: lessons from long-term followup of patients in the Euro-Lupus Nephritis Trial","volume":"50","author":"Houssiau FA","year":"2004","unstructured":"Houssiau FA, Vasconcelos C, D'Cruz D, et al.. Early response to immunosuppressive therapy predicts good renal outcome in lupus nephritis: lessons from long-term followup of patients in the Euro-Lupus Nephritis Trial. Arthritis Rheum. 2004, 50:3934-40. 10.1002\/art.20666","journal-title":"Arthritis Rheum"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00578-X","article-title":"Efficacy and safety of voclosporin versus placebo for lupus nephritis (AURORA 1): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial","volume":"397","author":"Rovin BH","year":"2021","unstructured":"Rovin BH, Teng YK, Ginzler EM, et al.. Efficacy and safety of voclosporin versus placebo for lupus nephritis (AURORA 1): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet. 2021, 397:2070-80. 10.1016\/S0140-6736(21)00578-X","journal-title":"Lancet"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa043731","article-title":"Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis","volume":"353","author":"Ginzler EM","year":"2005","unstructured":"Ginzler EM, Dooley MA, Aranow C, et al.. Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis. N Engl J Med. 2005, 353:2219-28. 10.1056\/NEJMoa043731","journal-title":"N Engl J Med"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1080\/17512433.2022.2092470","article-title":"Voclosporin: a novel calcineurin inhibitor for the treatment of lupus nephritis","volume":"15","author":"van Gelder T","year":"2022","unstructured":"van Gelder T, Lerma E, Engelke K, Huizinga RB. Voclosporin: a novel calcineurin inhibitor for the treatment of lupus nephritis. Expert Rev Clin Pharmacol. 2022, 15:515-29. 10.1080\/17512433.2022.2092470","journal-title":"Expert Rev Clin Pharmacol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1002\/art.42657","article-title":"Safety and efficacy of long-term voclosporin treatment for lupus nephritis in the phase 3 AURORA 2 clinical trial","volume":"76","author":"Saxena A","year":"2024","unstructured":"Saxena A, Ginzler EM, Gibson K, et al.. Safety and efficacy of long-term voclosporin treatment for lupus nephritis in the phase 3 AURORA 2 clinical trial. Arthritis Rheumatol. 2024, 76:59-67. 10.1002\/art.42657","journal-title":"Arthritis Rheumatol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/471609-rapid-reduction-in-proteinuria-with-the-initiation-of-voclosporin-in-lupus-nephritis-a-single-center-experience","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T14:47:12Z","timestamp":1774018032000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/471609-rapid-reduction-in-proteinuria-with-the-initiation-of-voclosporin-in-lupus-nephritis-a-single-center-experience"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,20]]},"references-count":18,"URL":"https:\/\/doi.org\/10.7759\/cureus.105557","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3,20]]}}}